BRPI0513982A - inibidores de sinalização de receptor de vegf e receptor de hgf - Google Patents

inibidores de sinalização de receptor de vegf e receptor de hgf

Info

Publication number
BRPI0513982A
BRPI0513982A BRPI0513982-1A BRPI0513982A BRPI0513982A BR PI0513982 A BRPI0513982 A BR PI0513982A BR PI0513982 A BRPI0513982 A BR PI0513982A BR PI0513982 A BRPI0513982 A BR PI0513982A
Authority
BR
Brazil
Prior art keywords
hgf
receptor signaling
vegf
receptor
signaling inhibitors
Prior art date
Application number
BRPI0513982-1A
Other languages
English (en)
Inventor
Arkadii Vaisburg
Stephen William
Franck Raeppel
Oscar Mario Saavedra
Naomy Berstein
Marie-Claude Granger
Lijie Zhan
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of BRPI0513982A publication Critical patent/BRPI0513982A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

INIBIDORES DE SINALIZAçãO DE RECEPTOR DE VEGF E RECEPTOR DE HGF. A presente invenção refere-se à inibição de sinalização de receptor de VEGF e sinalização de receptor de HGF. A invenção fornece compostos e métodos para inibir sinalização de receptor de VEGF e sinalização de receptor de HGF. A invenção também fornece composições e métodos para tratar doenças e condições proliferativas de célula.
BRPI0513982-1A 2004-07-30 2005-07-28 inibidores de sinalização de receptor de vegf e receptor de hgf BRPI0513982A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59291304P 2004-07-30 2004-07-30
US68303805P 2005-05-20 2005-05-20
PCT/CA2005/001177 WO2006010264A1 (en) 2004-07-30 2005-07-28 Inhibitors of vegf receptor and hgf receptor signaling

Publications (1)

Publication Number Publication Date
BRPI0513982A true BRPI0513982A (pt) 2007-11-27

Family

ID=35785877

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513982-1A BRPI0513982A (pt) 2004-07-30 2005-07-28 inibidores de sinalização de receptor de vegf e receptor de hgf

Country Status (13)

Country Link
US (2) US7772247B2 (pt)
EP (1) EP1781664B1 (pt)
JP (1) JP5096142B2 (pt)
KR (1) KR101257343B1 (pt)
CN (1) CN101031570B (pt)
AU (1) AU2005266803B2 (pt)
BR (1) BRPI0513982A (pt)
CA (1) CA2573538C (pt)
ES (1) ES2438017T3 (pt)
IL (1) IL180788A0 (pt)
MX (1) MX2007001216A (pt)
RU (1) RU2007107167A (pt)
WO (1) WO2006010264A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118588A1 (ja) * 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited 縮合複素環化合物
KR101257343B1 (ko) 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
WO2006113650A1 (en) * 2005-04-18 2006-10-26 Khan Saeed R Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs
CN101796055B (zh) * 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
AU2006313456B2 (en) * 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
JP2009526761A (ja) * 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
US8907091B2 (en) * 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
BRPI0908573A2 (pt) 2008-03-05 2012-12-25 Methylgene Inc inibidores da atividade de proteÍna tirosina quinase
EP2340244A4 (en) * 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
ES2578990T3 (es) * 2009-03-21 2016-08-03 Sunshine Lake Pharma Co., Ltd. Derivados de amino éster, sales de los mismos y métodos de uso
US8455484B2 (en) * 2010-04-16 2013-06-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
KR20130091331A (ko) 2010-07-16 2013-08-16 교와 핫꼬 기린 가부시키가이샤 함질소 방향족 복소환 유도체
MX2013003019A (es) 2010-09-15 2013-05-28 Hoffmann La Roche Compuestos de azabenzotiazol, composiciones y metodos de uso.
WO2012118632A1 (en) 2011-02-28 2012-09-07 Ning Xi Substituted quinoline compounds and methods of use
ES2895918T3 (es) 2012-02-21 2022-02-23 Towa Pharmaceutical Europe S L Composiciones farmacéuticas orales de dabigatrán etexilato
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
WO2014022117A1 (en) 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
MX2015010700A (es) 2013-02-21 2017-01-23 Calitor Sciences Llc Compuestos heteroaromaticos como moduladores de la p13 cinasa.
CA2918242C (en) 2013-07-31 2022-06-21 Merck Patent Gmbh Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
CN106588943B (zh) 2015-10-19 2018-10-16 广东东阳光药业有限公司 一种egfr抑制剂的盐、晶型及其用途
CN111032092A (zh) 2017-06-30 2020-04-17 韩国科学技术院 Vegf-grab蛋白与药物的缀合物及其用途
WO2019101178A1 (zh) 2017-11-24 2019-05-31 南京明德新药研发股份有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
JP2025508267A (ja) 2022-03-04 2025-03-21 パノロス バイオサイエンス インコーポレイテッド ＶＥＧＦ－Ｇｒａｂ及びＰＤ－１又はＰＤ－Ｌ１拮抗剤を含む併用投与用組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2003535867A (ja) 2000-06-06 2003-12-02 ファイザー プロダクツ インコーポレイテッド 抗癌剤として有用なチオフェン誘導体
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP2258366B1 (en) * 2001-06-22 2013-04-03 Kirin Pharma Kabushiki Kaisha Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
BR0308162A (pt) 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
DE10335598A1 (de) 2003-08-04 2005-02-24 Robert Bosch Gmbh Pedal-Vorrichtung für Kraftfahrzeuge
EP1660504B1 (en) 2003-08-29 2008-10-29 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
WO2005052872A1 (en) * 2003-11-21 2005-06-09 Facil, Llc Financial transaction system and method
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
EP1768984B1 (en) 2004-07-16 2010-10-20 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
KR101257343B1 (ko) 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CN101796055B (zh) * 2005-05-20 2013-09-04 梅特希尔基因公司 Vegf受体和hgf受体信号的抑制剂
AU2006313456B2 (en) * 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling

Also Published As

Publication number Publication date
KR101257343B1 (ko) 2013-04-23
US7772247B2 (en) 2010-08-10
WO2006010264A1 (en) 2006-02-02
EP1781664A4 (en) 2010-06-02
RU2007107167A (ru) 2008-09-10
EP1781664B1 (en) 2013-09-04
CN101031570A (zh) 2007-09-05
US20100216766A1 (en) 2010-08-26
IL180788A0 (en) 2007-06-03
CA2573538A1 (en) 2006-02-02
US20060074056A1 (en) 2006-04-06
EP1781664A1 (en) 2007-05-09
MX2007001216A (es) 2007-03-23
CN101031570B (zh) 2012-09-05
AU2005266803A1 (en) 2006-02-02
ES2438017T3 (es) 2014-01-15
CA2573538C (en) 2014-11-25
JP2008508192A (ja) 2008-03-21
JP5096142B2 (ja) 2012-12-12
US8470850B2 (en) 2013-06-25
AU2005266803B2 (en) 2011-10-27
KR20070051876A (ko) 2007-05-18

Similar Documents

Publication Publication Date Title
BRPI0513982A (pt) inibidores de sinalização de receptor de vegf e receptor de hgf
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
WO2007054831A3 (en) Inhibitors of vegf receptor and hgf receptor signaling
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
WO2007021941A3 (en) Inhibitors of voltage-gated sodium channels
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
WO2009012242A3 (en) Sodium channel inhibitors
CR10560A (es) Inhibidores de tirosina quinasa
CR9272A (es) Amino-imidazolonas para la inhibicion de b-secretasa
WO2007136714A3 (en) Integrase inhibitors
ATE524445T1 (de) Benzocycloheptapyridine als inhibitoren der tyrosinkinase met
WO2012040641A3 (en) Compounds for treating neurodegenerative diseases
TW200640924A (en) VEGF-R2 inhibitors and methods
MX2009006542A (es) Inhibidores de histona desacetilasa y sus profarmacos.
DK1761520T3 (da) Kinaseinhibitorer
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
PA8772701A1 (es) "COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO)-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA"
EA201170640A1 (ru) Дизамещенные фталазины-антагонисты сигнального пути hedgehog
WO2009067541A3 (en) Integrase inhibitors
DE602007008723D1 (de) Selektive rock-proteinkinasehemmer und ihre verwendung
BR112013011441B8 (pt) Compostos inibidores seletivos de glicosidases, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements